GBS hyperimmune IVIG

GBS hyperimmune IVIG is a specialized intravenously administered immune globulin (IVIG) product developed by immunizing plasma donors to achieve high levels of Group B Streptococcus (GBS) type-specific antibodies. This hyperimmune formulation exhibits significantly greater GBS type-specific opsonic activity compared to standard IVIG, demonstrating a >90% activity at a 1:1280 dilution versus 1:10 for standard IVIG. Preclinical studies in suckling rats showed 100% survival after GBS type-specific infection when treated with GBS hyperimmune IVIG, compared to less than or equal to 20% with standard IVIG. Clinical evaluation in neonates with suspected sepsis indicated that GBS hyperimmune IVIG, particularly at a 500 mg/kg dose, produced a sustained fourfold increase in serum GBS type-specific IgG for over six weeks, along with a correlated rise in opsonic activity, without observed adverse effects. The product aims to provide passive immunity against GBS infections, particularly in vulnerable populations like neonates.

Other names

hyperimmune IVIG